Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

00c1665a-432b-4c8e-bd04-90b6dff05013 - samples

ABSTRACT: RNAseq and WES of liver metastases samples (resections and biopsies) of CM and UM patients

PROVIDER: EGAD00001006577 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

RNAseq cutaneous and uveal melanoma liver metastases

Project description:RNA sequencing analyses of tumor liver metastases from untreated cutaneous melanoma (CM) and uveal melanoma (UM) patients.

| EGAS00001004794 | EGA

WES cutaneous and uveal melanoma liver metastases

Project description:Whole exome sequencing analyses of tumor liver metastases from untreated cutaneous melanoma (CM) and uveal melanoma (UM) patients.

| EGAS00001004795 | EGA

Proteome and Phosphoproteome of colorectal cancer liver metastases (CRLM), phosphoproteomics of AZD6482 treated CRC cell lines, phosphoproteomics of copanlisib treated xenograft

Project description:The research focuses on the longitudinal analysis of phosphoproteomic profiles in patients with recurrent colorectal liver metastases. Twenty-four individuals who underwent initial and recurrent resections for colorectal liver metastases participated in the study. Tissue samples were systematically collected throughout the treatment period from the liver metastases and normal liver tissue of each of the 24 patients at two timepoints. To validate the therapeutic candidate, we conducted a phosphoproteomics analysis of cell lines treated with AZD6482 and xenograft samples treated with copanlisib. The analysis aimed to assess the pharmacological effects of these treatments.

2025-01-30 | PXD048988 | JPOST Repository

Proteogenomics of colorectal cancer liver metastases

Project description:Colorectal cancer (CRC) is the third most common and second most deadly cancer worldwide. Treatments for metastatic CRC (mCRC) are still largely based on toxic chemotherapy regimens, but important insights into tumor biology enabled the development of targeted cancer therapies. Here, we describe a proteogenomic analysis of CRC liver metastases (metastatic CRC, mCRC), an ideal setting to analyze therapeutic resistance which occurs in a short time frame. We selected liver metastases from two CRC patients on both of which we performed deep proteome profiling and WES and RNAseq-directed database searches, identifying 10 predicted muttaions, one of which was KRAS G12V. finding we generated targeted parallel reaction monitoring (PRM) assays using stable isotope labelled standard (SIS) peptides to quantify the actual concentration (fmol per µg of total protein) of the mutated and canonical (wildtype) protein variants for 8 different mutations. We demonstrate on a total of 8 tumor and 6 paired healthy tissue samples (7 and 6 out of these KRASG12V) that PRM allows quantifying the actual mutation rate on the protein level from as little 10 µg of total protein starting amount and within a single 1 hour nano-LC-MS/MS run.

2019-12-04 | PXD014222 | Pride

Phase 1 Study Combining Alisertib with Nab-Paclitaxel in Patients with Advanced Solid Malignancies (NCT01677559)

Project description:WES and RNAseq from tumor samples of patients treated on clinical trial

2021-08-20 | GSE174765 | GEO

1,4-dihydroxy Quininib Activates Ferroptosis Pathways in Metastatic Uveal Melanoma and Reveals a Novel Prognostic Biomarker Signature

Project description:Uveal melanoma (UM) is an ocular cancer, with propensity for lethal liver metastases. When metastatic UM (MUM) occurs, as few as 8% of patients survive beyond two years. Efficacious treatments for MUM are urgently needed. 1,4-dihydroxy quininib, a cysteinyl leukotriene receptor 1 (CysLT1) antagonist, alters UM cancer hallmarks in vitro, ex vivo and in vivo. Here, we investigated the 1,4-dihydroxy quininib mechanism of action and its translational potential in MUM.

2024-06-16 | PXD046822 | Pride

caArray_notte-00422: Molecular Dissection of Colon Cancer

Project description:RNA expression data was generated as part of a colon cancer study. Samples were obtained from patients, including primary colon cancer, polyps, metastases, and matched normal mucosa (obtained from the margins of the resection). The RNA was extracted from tissue samples obtained from resections and hybridized to Affymetrix HG-U133 arrays. RNA expression data was also obtained for a few cell lines.

2015-05-02 | GSE68468 | GEO

Uveal Melanoma Human Vitreous Proteome

Project description:The purpose of the project was to profile protein expression liquid vitreous biopsies from uveal melanoma (UM) patients using mass spectrometry, to identify prognostic biomarkers, signaling pathways, and therapeutic targets. Vitreous biopsies were collected from two cohorts: comparative control eyes with epiretinal membranes (ERM) and test eyes with UM. Samples were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS).

2024-01-26 | PXD043403 | Pride

194d3f57-4752-4ed0-bd0c-3a9ab4381f62 - samples

Project description:This dataset includes NGS profiling of 13 women with simultaneous bilateral breast cancer. Seven women have WES of untreated surgical resections and matched healthy tissue. The six other women have WES of healthy tissue, WES+RNAseq of pre-neoadjuvant tumor biopsies, and when residual disease was present (6 tumors in 4 patients), WES+RNAseq of residual disease from post-neoadjuvant therapy surgery. One patient from the WES+RNAseq cohort had multifocal bilateral disease at diagnosis so there are 2 pre-neoadjuvant biopsy samples from each breast.

| EGAD00001009987 | EGA

RNAseq data of 81 liver cancer cell lines

Project description:A large panel of 81 liver cancer cell models, designated as LIver cancer MOdel REpository (LIMORE) was constructed. These cell lines include 31 public cell lines and 50 new cell models establishend from Chinese liver cancer patients. Whole genome sequencing (WGS), exome sequencing (WES) and RNA sequencing (RNAseq) were performed to obtain the genetic information for these cell lines. These cell lines and associated data provide new models and also a rich resource for liver cancer.

2019-06-17 | GSE97098 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data